Currently, there are 100.09M common shares owned by the public and among those 64.68M shares have been available to trade.
The company’s stock has a 5-day price change of -1.20% and -36.08% over the past three months. CLLS shares are trading -31.11% year to date (YTD), with the 12-month market performance down to -52.67% lower. It has a 12-month low price of $1.20 and touched a high of $3.38 over the same period. CLLS has an average intraday trading volume of 161.50K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.99%, -19.03%, and -35.89% respectively.
Institutional ownership of Cellectis ADR (NASDAQ: CLLS) shares accounts for 17.77% of the company’s 100.09M shares outstanding.
It has a market capitalization of $89.39M and a beta (3y monthly) value of 3.14. The earnings-per-share (ttm) stands at -$1.05. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.12% over the week and 7.42% over the month.
Earnings per share for the fiscal year are expected to increase by 42.44%, and -299.36% over the next financial year. EPS should shrink at an annualized rate of -27.53% over the next five years, compared to 1.69% over the past 5-year period.
Looking at the support for the CLLS, a number of firms have released research notes about the stock. Bryan Garnier stated their Buy rating for the stock in a research note on March 17, 2023, with the firm’s price target at $6. Robert W. Baird coverage for the Cellectis ADR (CLLS) stock in a research note released on May 18, 2022 offered a Outperform rating with a price target of $10. Wells Fargo was of a view on January 06, 2022 that the stock is Equal Weight, while JMP Securities gave the stock Mkt Outperform rating on November 30, 2021, issuing a price target of $20. William Blair on their part issued Mkt Perform rating on November 08, 2021.
